Related Experiment Video

Updated: May 11, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

[Clinical effects for patients with recurrent advanced non-small cell lung cancer treated with icotinib

Jingying Nong1, Na Qin, Jinghui Wang

  • 1Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis
and Thoracic Tumor Research Institute, Beijing 101149, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|May 17, 2013
PubMed
Abstract

Insights

Icotinib hydrochloride shows efficacy in recurrent advanced non-small cell lung cancer (NSCLC) patients, particularly those with EGFR mutations. This targeted therapy is well-tolerated, with mild side effects like rash and diarrhea.

Area of Science:

  • Oncology
  • Pharmacology

Context:

  • Advanced non-small cell lung cancer (NSCLC) is a significant global health challenge.
  • Icotinib hydrochloride represents a third-generation EGFR-TKI for NSCLC treatment.
  • Limited data exists on icotinib's efficacy in recurrent advanced NSCLC post-chemotherapy.

Purpose:

  • To evaluate the efficacy and survival outcomes of icotinib hydrochloride in advanced NSCLC patients.
  • To assess the safety and tolerability of icotinib hydrochloride.
  • To explore correlations between clinical features and treatment response in NSCLC.

Summary:

  • A retrospective analysis of 60 advanced NSCLC patients treated with icotinib hydrochloride was conducted.
  • The study observed an overall response rate (ORR) of 45.0% and a median progression-free survival (PFS) of 6.7 months.
  • Icotinib demonstrated superior efficacy in female patients, those receiving second-line treatment, and especially in EGFR mutation carriers, with mild side effects.

Impact:

  • Icotinib hydrochloride is an effective treatment option for recurrent advanced NSCLC, particularly for EGFR mutation-positive patients.
  • EGFR mutation status and specific mutations (e.g., exon 19 deletion) are significant prognostic factors for improved PFS.
  • The findings support icotinib's role in personalized medicine for NSCLC management.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...